Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors
10.3760/cma.j.cn371439-20200629-00036
- VernacularTitle:PARP抑制剂治疗铂耐药卵巢癌的研究进展
- Author:
Chenxi LI
;
Hongwei ZHAO
- From:
Journal of International Oncology
2021;48(3):180-183
- CountryChina
- Language:Chinese
-
Abstract:
Poly ADP-ribose polymerase(PARP)inhibitor is a targeted biological agent for the treatment of ovarian cancer, which is mainly suitable for platinum-sensitive ovarian cancer patients. However, data from clinical trials showed that PARP inhibitors have certain therapeutic effect on platinum-resistant or platinum-refractory ovarian cancer patients. It may become a new hope for treatment of ovarian cancer patients in the future.
